poisar

Stocks · News reference

Sensodyne Maker Haleon Leverages Eye-Level Shelf Placement To Outpace Rivals-Report

Vandana Singh

Haleon gains US market share at Walmart and Target by securing eye-level shelf placement with aggressive promotional strategies.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

GSKHLNTGTWMT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Will Ebiefung

    Could Investing $5,000 in D-Wave Quantum Stock Today Make You a Millionaire?

    D-Wave Quantum has surged over 1,000% in two years, but the article cautions that much of this rally is driven by hype rather than operational results. While the company shows strong booking growth (1,120% YoY), revenue remains flat at $3.1M and operating losses doubled to $53.3M. With a P/S ratio of 362, the stock is priced for perfection, and analysts suggest waiting for a lower entry point despite the transformational potential of quantum computing technology.

    QBTSGOOGGOOGLGOOGMGOOGN
  2. Sara Appino

    Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

    The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.

    MRNAVRTXMRKPFESNY
  3. Delveinsight

    Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight

    The complicated urinary tract infections (cUTI) market is expected to grow steadily through 2036, driven by rising antimicrobial resistance, increasing recurrent and hospital-acquired infections, and recent drug approvals. Key approvals include GSK/Spero Therapeutics' UTEBZI (oral antibiotic) and Wockhardt's ZAYNICH (intravenous antibiotic), both approved in 2026. Emerging therapies from companies like Venatorx Pharmaceuticals, Meiji Seika Pharma, and Locus Biosciences targeting multidrug-resistant Gram-negative bacteria are expected to further expand the market.

    GSKSPRO
  5. Na

    THE BUSINESS COUNCIL ANNOUNCES LEADERSHIP TRANSITION AS GOLDMAN SACHS CEO DAVID SOLOMON TAKES THE HELM

    David Solomon, CEO of Goldman Sachs, has been named the new chair of The Business Council, succeeding Brian Cornell of Target Corporation. Solomon will lead the organization during a pivotal period marked by AI advancement and complex global economic challenges. The Business Council, established in 1933, serves as a forum for world-leading CEOs to collaborate on business solutions.

    GSGSPAGSPCGSPDTGT
  6. Ben Gran

    What the Latest Fed Decision Means for Costco, Walmart, Target, and Home Depot

    The Federal Reserve's 0.25% rate hike in September, with inflation at 3.7%, signals potential additional hikes in 2026. Rising interest rates affect retail stocks differently: Costco and Walmart are positioned to benefit from higher inflation and affluent consumers trading down, while Home Depot faces headwinds from reduced home improvement spending due to higher mortgage rates. Target's turnaround momentum could be threatened by inflation-weary consumers seeking bargains.

    COSTHDTGTWMT